=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,X,Ak,NO2

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 06:51:32 ON 25 JUN 2003)

FILE 'REGISTRY' ENTERED AT 06:51:40 ON 25 JUN 2003
L1 STRUCTURE UPLOADED
L2 7 S L1
L3 84 S L1 FULL
L4 84 S L3 AND CAPLUS/LC
L5 0 S L3 AND CAOLD/LC

FILE 'CAPLUS' ENTERED AT 06:52:56 ON 25 JUN 2003
L6 3 S L3

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:34889 CAPLUS
DOCUMENT NUMBER: 130:95549
TITLE: Preparation of N-sulfonyl(benzylamino)benzamide, N-sulfonylbenzylimidazolepropanamide, and N-sulfonylpyridinecarboxamide having hypoglycemic and phosphodiesterase 5 (PDE 5) inhibitory activities
INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Hiramura, Takahiro; Onomura, Osamu; Nishikawa, Masahiro; Kayakiri, Hiroshi; Abe, Yoshito; Hamashima, Hitoshi; Sawada, Hitoshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9900359	A1	19990107	WO 1998-JP2886	19980626
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1000932	A1	20000517	EP 1998-929724	19980626
R: CH, DE, ES, FR, GB, IT, LI				
US 6242474	B1	20010605	US 2000-446619	20000321

PRIORITY APPLN. INFO.: JP 1997-187849 A 19970627
WO 1998-JP2886 W 19980626
OTHER SOURCE(S): MARPAT 130:95549
GI



I



II

AB Novel arom. ring derivs. represented by general formula [I; R2 = (un)substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl; ch1, ch2 = (un)branched satd. or unsatd. bridging group wherein ch1 is optionally substituted by lower alkyl, lower cycloalkyl,

aryl, heterocyclyl, lower alkyl-lower cycloalkyl, aryl-lower alkyl, or heterocyclyl-lower alkyl; Nu = 5- or 6-membered ring; X and Nu may be directly linked to each other; R1 = H, halo, lower alkyl, NH2, acylamino, lower alkyl alkenyl, alkynyl, halo-lower alkyl, lower cycloalkyl, NO2, lower alkyl-amino, CO2H or its ester, amidated CO2H, lower alkanesulfonyl, arylsulfonyl, OH, lower alkoxy; n = integer of .ltoreq.2; A = (un)substituted aryl] or pharmaceutically acceptable salts thereof are prepd. Because of having hypoglycemic and PDE 5 inhibitory activities, these compds. and salts thereof are useful as remedies for impaired glucose tolerance, diabetes, complication of diabetes, insulin-resistant syndrome, polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension, angina pectoris, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal insufficiency, atherosclerosis, angiostenosis, peripheral vascular diseases, cerebral stroke, chronic reversible obstructive diseases, autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by disordered intestinal motion, sexual impotence, nephritis, cachexia, pancreatitis, post-(percutaneous transluminal coronary angioplasty) PTCA reconstriction, etc. Thus, (E)-3-(4-bromo-1-(2,4-dichlorobenzyl)-2-methylimidazol-5-yl)-2-propenoic acid was stirred with N,N'-carbonyl diimidazole in DMF at room temp. for 1 h and then condensed with pentanesulfonamide in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene at 100.degree. for 3 h to give the title compd. (II). Another compd., 4-(acetamido)-3-(N-methyl-2,4-dichlorobenzylamino)-[N-(n-pentanesulfonyl)]benzamide (III) (prepn. given), lowered glucose and triglyceride level by 60 and 104%, resp., when a feed contg. 0.01% III was fed to mice twice per wk for 14 days.

IT **219503-80-7P 219503-84-1P 219503-86-3P**
219503-88-5P 219503-90-9P 219504-01-5P
219504-02-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-sulfonyl(benzylamino)benzamide, N-sulfonylbenzylimidazolepropanamide, and N-sulfonylpyridinecarboxamide having hypoglycemic and phosphodiesterase 5 inhibitory activities as drugs)

RN 219503-80-7 CAPLUS

CN 2-Propenamide, 3-[4-bromo-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 219503-84-1 CAPLUS
CN 1H-Imidazole-5-propanamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)



RN 219503-86-3 CAPLUS
CN 2-Propenamide, 3-[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 219503-88-5 CAPLUS
CN 2-Propenamide, 3-[4-chloro-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 219503-90-9 CAPLUS
CN 2-Propenamide, 3-[4-chloro-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(phenylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 219504-01-5 CAPLUS
CN 2-Thiophenepropanamide, .alpha.-[[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]methylene]-N-(pentylsulfonyl)-, (.alpha.E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 219504-02-6 CAPLUS
CN Benzenepropanamide, .alpha.-[[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]methylene]-N-(pentylsulfonyl)-, (.alpha.E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT